Cargando…

Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer

In contrast to venous thromboembolism, little is known about arterial thromboembolism in patients with cancer. The aim of this study was to quantify the risk and explore clinical risk factors of arterial thromboembolism in patients with cancer, and investigate its potential impact on mortality. Pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grilz, Ella, Königsbrügge, Oliver, Posch, Florian, Schmidinger, Manuela, Pirker, Robert, Lang, Irene M., Pabinger, Ingrid, Ay, Cihan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119137/ https://www.ncbi.nlm.nih.gov/pubmed/29794142 http://dx.doi.org/10.3324/haematol.2018.192419

Ejemplares similares

Association of complete blood count parameters, d‐dimer, and soluble P‐selectin with risk of arterial thromboembolism in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2019)

Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2019)

Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study
por: Ay, Cihan, et al.
Publicado: (2022)

Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D‐Dimer analysis: A prospective study
por: Posch, Florian, et al.
Publicado: (2020)

Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry
por: Königsbrügge, Oliver, et al.
Publicado: (2016)

Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality
por: Riedl, Julia, et al.
Publicado: (2014)

Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI)
por: Königsbrügge, Oliver, et al.
Publicado: (2017)

Bleeding phenotype in nonsevere hemophilia by International Society on Thrombosis and Haemostasis bleeding assessment tool, bleeding frequency, and the joint status
por: Rejtő, Judit, et al.
Publicado: (2023)

Antithrombin Activity and Association with Risk of Thrombosis and Mortality in Patients with Cancer
por: Englisch, Cornelia, et al.
Publicado: (2022)

Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non‐severe haemophilia A
por: Rejtő, Judit, et al.
Publicado: (2020)

A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability
por: Königsbrügge, Oliver, et al.
Publicado: (2016)

Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study
por: Moik, Florian, et al.
Publicado: (2020)

Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis
por: Nopp, Stephan, et al.
Publicado: (2020)

Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized controlled trials
por: Moik, Florian, et al.
Publicado: (2020)

ABO blood group type and risk of venous thromboembolism in patients with cancer
por: Englisch, Cornelia, et al.
Publicado: (2022)

Pulmonary embolism during the COVID‐19 pandemic: Decline in diagnostic procedures and incidence at a university hospital
por: Nopp, Stephan, et al.
Publicado: (2020)

Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer
por: Moik, Florian, et al.
Publicado: (2020)

Alterations of the Platelet Proteome in Lung Cancer: Accelerated F13A1 and ER Processing as New Actors in Hypercoagulability
por: Ercan, Huriye, et al.
Publicado: (2021)

Atrial fibrillation in patients with end‐stage renal disease on hemodialysis: Magnitude of the problem and new approach to oral anticoagulation
por: Königsbrügge, Oliver, et al.
Publicado: (2019)

Atrial fibrillation and anticoagulation are associated with hospitalisations in patients with end-stage kidney disease on haemodialysis: a prospective population-based cohort study
por: Steiner, Daniel, et al.
Publicado: (2022)

Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma
por: Mir Seyed Nazari, Pegah, et al.
Publicado: (2020)

A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts
por: Muñoz, Andrés, et al.
Publicado: (2023)

How I treat cancer-associated thrombosis
por: Moik, Florian, et al.
Publicado: (2020)

Circulatory miR-411-5p as a Novel Prognostic Biomarker for Major Adverse Cardiovascular Events in Patients with Atrial Fibrillation
por: Nopp, Stephan, et al.
Publicado: (2023)

Extracellular Vesicle-Associated Tissue Factor Activity in Prostate Cancer Patients with Disseminated Intravascular Coagulation
por: Hell, Lena, et al.
Publicado: (2021)

Low extracellular vesicle–associated tissue factor activity in patients with persistent lupus anticoagulant and a history of thrombosis
por: Hell, Lena, et al.
Publicado: (2018)

P1663: THE EFFECTS OF OBESITY ON BLEEDING FREQUENCY AND PARAMETERS OF FIBRINOLYSIS IN PATIENTS WITH NON-SEVERE HEMOPHILIA
por: Königsbrügge, O., et al.
Publicado: (2022)

Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant
por: Posch, Florian, et al.
Publicado: (2017)

Lupus anticoagulant test persistence over time and its associations with future thrombotic events
por: Colling, Meaghan E., et al.
Publicado: (2022)

Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art
por: Thaler, Johannes, et al.
Publicado: (2015)

Altered platelet proteome in lupus anticoagulant (LA)-positive patients—protein disulfide isomerase and NETosis as new players in LA-related thrombosis
por: Hell, Lena, et al.
Publicado: (2020)

Fibrinolysis and bleeding of unknown cause
por: Mehic, Dino, et al.
Publicado: (2021)

Plasma Clot Properties in Patients with Pancreatic Cancer
por: Thaler, Johannes, et al.
Publicado: (2023)

Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants
por: Ay, C, et al.
Publicado: (2019)

Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
por: Moik, Florian, et al.
Publicado: (2021)

Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients
por: Bianconi, Daniela, et al.
Publicado: (2015)

Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma
por: Mir Seyed Nazari, Pegah, et al.
Publicado: (2019)

Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting
por: Ay, Cihan, et al.
Publicado: (2020)

Health-related quality of life is impaired in bleeding disorders of unknown cause: results from the Vienna Bleeding Biobank
por: Mehic, Dino, et al.
Publicado: (2023)

Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria
por: Ay, Cihan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sadk7e5d5dpekmort0vksn2bhl